LL-37 (Cathelicidin) vs Tirzepatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
LL-37 (Cathelicidin)
LL-37 is the only human cathelicidin antimicrobial peptide. It plays crucial roles in innate immunity and has shown diverse biological activities including antimicrobial, immunomodulatory, and wound healing properties.
Full details →Tirzepatide
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials.
Full details →Side-by-Side Comparison
| Aspect | LL-37 (Cathelicidin) | Tirzepatide |
|---|---|---|
| Mechanism | Disrupts bacterial membranes, neutralizes endotoxins, modulates immune cell function, and promotes wound healing. Has both direct antimicrobial and immunomodulatory effects. | Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, providing synergistic effects on insulin secretion, appetite suppression, and metabolic regulation. The dual mechanism may explain its enhanced efficacy. |
| Typical Dosage | Research protocols vary widely. Typical ranges: 50-200mcg administered subcutaneously 2-3 times weekly. Some protocols use higher doses for acute infections. | Start at 2.5mg weekly, titrate every 4 weeks through 5mg, 7.5mg, 10mg, 12.5mg, to maximum 15mg weekly. Full titration takes approximately 20 weeks. |
| Administration | Subcutaneous injection. Can cause significant injection site reactions. Often used in conjunction with other immune-supporting protocols. | Subcutaneous injection once weekly. Rotate injection sites. Slower titration may help reduce GI side effects. |
| Side Effects | Injection site pain and reactions are common. May cause flu-like symptoms, temporary fatigue, or immune activation responses. | Similar to semaglutide: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite. Generally improve with continued use. |
| Best For |